Psychiatry

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

A new study found unvaccinated people have a greater risk of depression or serious mental health illnesses compared to vaccinated people.

Uric acid levels, commonly used to indicate gout, are closely associated with bipolar-affected mania.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

A new study found approximately 40% with osteoarthritis and 36.3% with RA screened positive for anxiety, depression, and fibromyalgia.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

In an interview with HCPLive, Angela Moreland, PhD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.

In a "secret shopper" study, investigators posing as Medicaid enrollees found many clinicians in Medicaid provider directories do not accept Medicaid insurance.

A year after zuranolone’s FDA approval for postpartum depression on August 3, 2023, prescribers and a patient weigh in about the medication’s success in alleviating symptoms.

Investigators found patients with comorbid temporomandibular disorder, migraines, and fibromyalgia experienced longer pain duration than patients with only 1 comorbidity.

This month in review captures the top news in the psychiatry field during July.

This extended-release injectable suspension for schizophrenia and schizoaffective disorder is approved as a monotherapy and as an adjunct to mood stabilizers or antidepressants.

A new study found using e-cigarettes with partial nicotine reduction was linked to greater puffing time, puff duration, and total inhaled volume than 5% nicotine concentration.

A new study found the group with the shortest seizure duration of ≤ 20 seconds had the lowest remission rate of 27.2%, compared with a 39.3% overall remission rate.